Stockscreener 앱 받기
31.82
1.73%
0.54
시간 외 거래:
31.84
0.02
+0.06%
전일 마감가:
$31.28
열려 있는:
$31.33
하루 거래량:
222.29K
Relative Volume:
0.64
시가총액:
$3.89B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+16.51%
1개월 성능:
+10.49%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$30.23
$31.97
1주일 범위
$27.36
$33.15
52주 변동 폭
$24.51
$34.47
Parabilis Medicines Inc Stock (PBLS) Company Profile
Compare PBLS vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PBLS
Parabilis Medicines Inc
|
31.82 | 3.83B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Parabilis Medicines Inc 주식(PBLS)의 최신 뉴스
Parabilis Medicines, Inc. Revenue Breakdown – NASDAQ:PBLS - TradingView
PBLS|Parabilis Medicines Ord Shs|Price:31.280|Chg%:-1.530 - TradingKey
Scribe secures $129M in a rare gene editing IPO - BioPharma Dive
Parabilis Medicines(PBLS.US) 10% Shareholder Buys US$6.92 Million in Common Stock - Moomoo
Form 4 Parabilis Medicines For: 22 July - Investing.com India
Form 4 Parabilis Medicines For: 22 July By Investing.com - Investing.com South Africa
Parabilis Medicines, Inc. (PBLS) Revenue (TTM) - Zacks Investment Research
RA Capital boosts stake in Parabilis Medicines (PBLS) with stock buys - Stock Titan
Parabilis Medicines (PBLS) 10K Form and Latest SEC Filings 2026 - MarketBeat
Parabilis tops Kailera as biopharma IPOs surge to best H1 since 2021 - BioWorld News
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
LifeSci Capital Initiates Parabilis Medicines(PBLS.US) With Buy Rating, Announces Target Price $42 - Moomoo
With record listing prices, what the mid-year IPO market says about the current state of biopharma - The Pharma Letter
Primary Markets Group June 2026 U.S. IPO Update - Seeking Alpha
Parabilis Medicines, Inc. (NASDAQ:PBLS) Sees Significant Increase in Short Interest - MarketBeat
PBLS Price Today: Parabilis Medicines, Inc. Stock Price, Quote & Chart - mexc.co
Parabilis Medicines, Inc.'s Quiet Period Set To Expire on July 20th (NASDAQ:PBLS) - MarketBeat
Teresa Jurgensen Net Worth (2026) - GuruFocus
Thomas Rodolpho Kotarakos Net Worth (2026) - GuruFocus
Helen Huei In Ho Net Worth (2026) - GuruFocus
Soleus Capital Management, L.p. Net Worth (2026) - GuruFocus
Soleus Pe Gp Iii, Llc Net Worth (2026) - GuruFocus
Soleus Gp, Llc Net Worth (2026) - GuruFocus
Parabilis Medicines Inc. (PBLS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
PBLS Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
Mohammed Fawzi Benzaghou Net Worth (2026) - GuruFocus
Parabilis Medicines (NASDAQ:PBLS) Rating Increased to Hold at Zacks Research - MarketBeat
PBLS|Parabilis Medicines Ord Shs|Price:29.510|Chg%:-0.840 - TradingKey
This Parabilis Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Sahm
Leerink Partners Initiates Parabilis Medicines(PBLS.US) With Buy Rating, Announces Target Price $40 - Moomoo
A Quick Look at Today's Ratings for Parabilis Medicines(PBLS.US), With a Forecast Between $40 to $45 - Moomoo
Leerink initiates Parabilis Medicines stock with Outperform rating By Investing.com - Investing.com South Africa
BofA Securities initiates Parabilis Medicines stock coverage with buy rating By Investing.com - Investing.com Nigeria
The biggest biotech funding rounds in June 2026 - Labiotech.eu
PBLS Initiated Coverage by Leerink Partners -- Rating Set to Out - GuruFocus
Parabilis Medicines Price Target Announced at $40.00/Share by Guggenheim - Moomoo
Analyst Initiates Buy on Parabilis, Citing First-in-Class Wnt Inhibitor Zolucatidine and Strong Cash Runway - TipRanks
Michael Schmidt Initiates Buy on Parabilis Medicines, Citing Helicon Platform and Zolucatetide as Key Value Drivers with $40 Price Target - TipRanks
BofA Securities initiates Parabilis Medicines stock coverage with buy rating - Investing.com
Leerink initiates Parabilis Medicines stock with Outperform rating - Investing.com
Guggenheim initiates Parabilis Medicines stock with buy rating By Investing.com - Investing.com Nigeria
Guggenheim initiates Parabilis Medicines stock with buy rating - Investing.com
Large VC financings improve in H1 2026 - BioWorld News
Nasdaq Delivers the Strongest First Half in U.S. Exchange History as Public Markets Momentum Builds - Moomoo
Mass. biotech IPO proceeds near $3.2B, close in on pandemic-era record pace - The Business Journals
Insider Stock Purchases: June 29, 2026 - Quiver Quantitative
[Form 4] Parabilis Medicines, Inc. Insider Trading Activity - Stock Titan
Parabilis Medicines (PBLS) holder reports 527,070-share Series F position - Stock Titan
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested - Yahoo Finance
Price to earnings forward of Parabilis Medicines, Inc. – NASDAQ:PBLS - TradingView
Price to book forward of Parabilis Medicines, Inc. – NASDAQ:PBLS - TradingView
Parabilis Medicines Inc (PBLS) 재무 분석
Parabilis Medicines Inc (PBLS)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):